439087-18-0

Elobixibat (0.27 mg/kg/day for 20 weeks, p.o.) inhibits tumor growth in the mouse model of fatty liver disease by inhibiting bile acid reabsorption and reducing total and primary bile acid levels in serum and liver^[2].
Elobixibat (5 days a week for 4 weeks, 0.2, 0.6, or 1.2 mg/kg/day, gavage) improves NASH-related histopathology, reduces cytokine (TNF-α, IL-6, and TGF-β) expression, and normalizes gut microbiome composition in nonsteatohepatitis (NASH) mouse models^[3].